MARKET

TCON

TCON

TRACON Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.43
-0.27
-2.52%
After Hours: 10.22 -0.21 -2.01% 19:41 01/26 EST
OPEN
10.72
PREV CLOSE
10.70
HIGH
11.49
LOW
10.35
VOLUME
732.66K
TURNOVER
--
52 WEEK HIGH
12.20
52 WEEK LOW
0.9500
MARKET CAP
159.53M
P/E (TTM)
-3.3651
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
TRACON Pharma nabs priority review status for envafolimab in China
TRACON Pharma ([[TCON]] +3.0%) announces its corporate partners, Alphamab Oncology and 3D Medicines, have received notification that the New Drug Application for envafolimab was granted priority review by the Center
Seekingalpha · 01/19 16:09
BRIEF-Tracon Pharmaceuticals Announces Acceptance Of The Envafolimab NDA By The NMPA In China For Priority Review
reuters.com · 01/19 14:54
Tracon Pharmaceuticals' Partners Get OK for New Drug Application in China for Cancer Treatment
MT Newswires · 01/19 13:54
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review
SAN DIEGO, Jan 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage...
GlobeNewswire · 01/19 13:38
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review
NDA was Submitted in November by TRACON’s Corporate Partners, Alphamab Oncology and 3D Medicines, in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric CancerSAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCO...
GlobeNewswire · 01/19 13:05
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner ...
GlobeNewswire · 01/19 13:05
TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner...
GlobeNewswire · 01/06 13:05
The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 4)
Benzinga · 01/05 13:38
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TCON. Analyze the recent business situations of TRACON Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TCON stock price target is 9.17 with a high estimate of 12.00 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 6.22M
% Owned: 40.67%
Shares Outstanding: 15.30M
TypeInstitutionsShares
Increased
3
33.49K
New
18
4.44M
Decreased
4
277.22K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
President/Chief Executive Officer/Director
Charles Theuer
Executive Vice President
Bonne Adams
Other
H Logan
Executive Vice President
Suzy Benedict
Chief Accounting Officer
Scott Brown
Other
Mark Wiggins
Director
Saundra Pelletier
Independent Director
William LaRue
Independent Director
Martin Mattingly
Independent Director
J. Rainer Twiford
Independent Director
Stephen Worland
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About TCON
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Webull offers kinds of TRACON Pharmaceuticals Inc stock information, including NASDAQ:TCON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCON stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TCON stock methods without spending real money on the virtual paper trading platform.